BiotechTube

Bupivacaine HCl

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Analgesia

Conditions

Analgesia

Trial Timeline

Sep 19, 2018 → Nov 5, 2018

NCT ID
NCT03705065

About Bupivacaine HCl

Bupivacaine HCl is a approved stage product being developed by Heron Therapeutics for Analgesia. The current trial status is completed. This product is registered under clinical trial identifier NCT03705065. Target conditions include Analgesia.

What happened to similar drugs?

4 of 9 similar drugs in Analgesia were approved

Approved (4) Terminated (0) Active (5)
✅Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
✅HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
✅Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
✅Bupivacaine Hydrochloride + Bupivacaine Hydrochloride + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
🔄Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
🔄HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3
🔄HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03705065ApprovedCompleted

Competing Products

20 competing products in Analgesia

See all competitors
ProductCompanyStageHype Score
AcetaminophenJohnson & JohnsonPhase 2
42
HRF2105 patch + Loxoprofen patch + placeboJiangsu Hengrui MedicinePhase 2
31
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
29
Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
50
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
38
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride InjectionJiangsu Hengrui MedicinePhase 2
42
Org 28611 + morphine sulfate + PlaceboMerckPhase 2
27
oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloridePfizerPhase 1
29
Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
40
HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3
40
Experimental: stage I：HSK21542 0.4 μg/kg + Experimental: stage I：HSK21542 1 μg/kg + Experimental: stage I：HSK21542 0.5μg/kg + Experimental: stage I：HSK21542 1μg/kg + Experimental: stage II：HSK21542 0.5μg/kg + Experimental: stage II：HSK21542 1μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
35
Stage I: HSK21542 0.5 μg/kg + Stage I: HSK21542 1 μg/kg + HSK21542 0.5 μg/kg + HSK21542 1 μg/kg + HSK21542 2 μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
35
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
40
HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
30
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
33
HTX-011 + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 2
25
HTX-011 + PlaceboHeron TherapeuticsPhase 2
25
HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 3
30
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
33
HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011Heron TherapeuticsPhase 2
17